{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:26:49Z","timestamp":1724891209408},"reference-count":185,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,27]]},"DOI":"10.7759\/cureus.67977","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T04:55:45Z","timestamp":1724820945000},"source":"Crossref","is-referenced-by-count":0,"title":["The Potential of Ambroxol as a Panacea for Neonatal Diseases: A Scoping Review"],"prefix":"10.7759","author":[{"given":"Sameer Y","family":"Al-Abdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Al-Aamri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/1389557521666210226152238","article-title":"Adhatoda vasica (Nees.): a review on its botany, traditional uses, phytochemistry, pharmacological activities and toxicity","volume":"21","author":"Shamsuddin T","year":"2021","unstructured":"Shamsuddin T, Alam MS, Junaid M, Akter R, Hosen SM, Ferdousy S, Mouri NJ. Adhatoda vasica (Nees.): a review on its botany, traditional uses, phytochemistry, pharmacological activities and toxicity. Mini Rev Med Chem. 2021, 21:1925-64. 10.2174\/1389557521666210226152238","journal-title":"Mini Rev Med Chem"},{"key":"ref2","article-title":"A phyto-pharmacological overview on Adhatoda zeylanica Medic. syn. A. vasica (Linn.) Nees","volume":"8","author":"Ahmad S","year":"2009","unstructured":"Ahmad S, Garg M, Ali M, Singh M, Athar MT, Ansari SH. A phyto-pharmacological overview on Adhatoda zeylanica Medic. syn. A. vasica (Linn.) Nees. Nat Prod Radiance. 2009, 8:549-54.","journal-title":"Nat Prod Radiance"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.8.1119","article-title":"Ambroxol in the 21st century: pharmacological and clinical update","volume":"4","author":"Malerba M","year":"2008","unstructured":"Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol. 2008, 4:1119-29. 10.1517\/17425255.4.8.1119","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.24252\/djps.v6i1.38401","article-title":"The use of an ambroxol solution to assess acute dermal irritation on rabbit skin","volume":"5","author":"Wahyuddin M","year":"2023","unstructured":"Wahyuddin M, Mukhriani, Vera O, Ika Puspita S, Rizka Humardewayanti A, Titik N. The use of an ambroxol solution to assess acute dermal irritation on rabbit skin. Ad-Dawaa\u2019 J Pharm Sci. 2023, 5:69-79. 10.24252\/djps.v6i1.38401","journal-title":"Ad-Dawaa\u2019 J Pharm Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2007.00032.x","article-title":"Ambroxol: a CNS drug?","volume":"14","author":"Weiser T","year":"2008","unstructured":"Weiser T. Ambroxol: a CNS drug?. CNS Neurosci Ther. 2008, 14:17-24. 10.1111\/j.1527-3458.2007.00032.x","journal-title":"CNS Neurosci Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2011.629646","article-title":"Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood","volume":"6","author":"Paleari D","year":"2011","unstructured":"Paleari D, Rossi GA, Nicolini G, Olivieri D. Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood. Expert Opin Drug Discov. 2011, 6:1203-14. 10.1517\/17460441.2011.629646","journal-title":"Expert Opin Drug Discov"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.11669\/cpj.2015.09.019","article-title":"[Current clinical application of ambroxol hydrochloride injection and consideration on the rational drug use]","volume":"50","author":"Fan QQ","year":"2015","unstructured":"Fan QQ, Zhang B, Li DK, Mei D. [Current clinical application of ambroxol hydrochloride injection and consideration on the rational drug use]. Chin Pharm J. 2015, 50:816-20. 10.11669\/cpj.2015.09.019","journal-title":"Chin Pharm J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-002-0116-7","article-title":"Pharmacoeconomic analysis of prescriptions in Italian pediatric general practice","volume":"3","author":"Campi R","year":"2002","unstructured":"Campi R, Garattini L, Tediosi F, Bonati M. Pharmacoeconomic analysis of prescriptions in Italian pediatric general practice. Eur J Health Econ. 2002, 3:261-6. 10.1007\/s10198-002-0116-7","journal-title":"Eur J Health Econ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1335058","article-title":"Exploring the efficacy and safety of ambroxol in Gaucher disease: an overview of clinical studies","volume":"15","author":"Mohamed FE","year":"2024","unstructured":"Mohamed FE, Al-Jasmi F. Exploring the efficacy and safety of ambroxol in Gaucher disease: an overview of clinical studies. Front Pharmacol. 2024, 15:1335058. 10.3389\/fphar.2024.1335058","journal-title":"Front Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122909","article-title":"Beyond the lungs: exploring diverse applications of bromhexine and ambroxol","volume":"353","author":"Ahmadi E","year":"2024","unstructured":"Ahmadi E, Afrooghe A, Soltani ZE, Elahi M, Shayan M, Ohadi MA, Dehpour AR. Beyond the lungs: exploring diverse applications of bromhexine and ambroxol. Life Sci. 2024, 353:122909. 10.1016\/j.lfs.2024.122909","journal-title":"Life Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/C2020-0-02133-X","article-title":"Avery's Diseases of the Newborn","author":"Sawyer T","year":"2023","unstructured":"Sawyer T, Gleason CA. Avery's Diseases of the Newborn. Elsevier Health Sciences, Philadelphia, PA; 2023. 10.1016\/C2020-0-02133-X"},{"key":"ref12","article-title":"Fanaroff and Martin's Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant","author":"Martin RJ","year":"2024","unstructured":"Martin RJ, Fanaroff AA. Fanaroff and Martin's Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant. Elsevier, Philadelphia, PA; 2024."},{"key":"ref13","article-title":"Rennie & Roberton's Textbook of Neonatology","author":"Rennie JM","year":"2012","unstructured":"Rennie JM. Rennie & Roberton's Textbook of Neonatology.  Elsevier, Philadelphia, PA; 2012."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5772\/63384","article-title":"Alternative therapies for the management of respiratory distress syndrome","author":"Alejandro GG","year":"2016","unstructured":"Alejandro GG, Vicente GB. Alternative therapies for the management of respiratory distress syndrome. Respiratory Management of Newborns. Hany A, Hesham AH (ed): IntechOpen, Rijeka, Croatia; 2016. 2:11-23. 10.5772\/63384"},{"key":"ref15","article-title":"Antiinflammatory properties of ambroxol","volume":"13","author":"Beeh KM","year":"2008","unstructured":"Beeh KM, Beier J, Esperester A, Paul LD. Antiinflammatory properties of ambroxol. Eur J Med Res. 2008, 13:557-62.","journal-title":"Eur J Med Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-004-0050-3","article-title":"In vitro and in vivo antioxidant activity of ambroxol","volume":"4","author":"Stetinov\u00e1 V","year":"2004","unstructured":"Stetinov\u00e1 V, Herout V, Kvetina J. In vitro and in vivo antioxidant activity of ambroxol. Clin Exp Med. 2004, 4:152-8. 10.1007\/s10238-004-0050-3","journal-title":"Clin Exp Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2768365","article-title":"Oxidative stress related diseases in newborns","volume":"2016","author":"Ozsurekci Y","year":"2016","unstructured":"Ozsurekci Y, Aykac K. Oxidative stress related diseases in newborns. Oxid Med Cell Longev. 2016, 2016:2768365. 10.1155\/2016\/2768365","journal-title":"Oxid Med Cell Longev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0127-7","article-title":"Bronchopulmonary dysplasia","volume":"5","author":"Th\u00e9baud B","year":"2019","unstructured":"Th\u00e9baud B, Goss KN, Laughon M, et al.. Bronchopulmonary dysplasia. Nat Rev Dis Primers. 2019, 5:78. 10.1038\/s41572-019-0127-7","journal-title":"Nat Rev Dis Primers"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.52768\/jjgastro\/1104","article-title":"Acetamiprid induced oxidative stress and genotoxicity in male albino rats: attenuation by ambroxol","volume":"2","author":"Eltoweissy MY","year":"2022","unstructured":"Eltoweissy MY, El-Din EME, Osman KA. Acetamiprid induced oxidative stress and genotoxicity in male albino rats: attenuation by ambroxol. Jpn J Gastroenterol Hepatol. 2022, 2:1-8. 10.52768\/jjgastro\/1104","journal-title":"Jpn J Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8131286","article-title":"Ambroxol improves neuronal survival and reduces white matter damage through suppressing endoplasmic reticulum stress in microglia after intracerebral hemorrhage","volume":"2020","author":"Jiang X","year":"2020","unstructured":"Jiang X, Zhang J, Kou B, et al.. Ambroxol improves neuronal survival and reduces white matter damage through suppressing endoplasmic reticulum stress in microglia after intracerebral hemorrhage. Biomed Res Int. 2020, 2020:8131286. 10.1155\/2020\/8131286","journal-title":"Biomed Res Int"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1691\/ph.2017.7541","article-title":"Effects and mechanisms of ambroxol inhalation (Mucosolvan(\u00ae)) in the treatment of neonatal pneumonia","volume":"72","author":"Yang Z","year":"2017","unstructured":"Yang Z, Xiao X, Huang Y, He X, Lu Q, Chen S, Lin Z. Effects and mechanisms of ambroxol inhalation (Mucosolvan(\u00ae)) in the treatment of neonatal pneumonia. Pharmazie. 2017, 72:604-7. 10.1691\/ph.2017.7541","journal-title":"Pharmazie"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad099","article-title":"Repurposing the mucolytic agent ambroxol for treatment of sub-acute and chronic ischaemic stroke","volume":"5","author":"Patzwaldt K","year":"2023","unstructured":"Patzwaldt K, Berezhnoy G, Ionescu T, et al.. Repurposing the mucolytic agent ambroxol for treatment of sub-acute and chronic ischaemic stroke. Brain Commun. 2023, 5:fcad099. 10.1093\/braincomms\/fcad099","journal-title":"Brain Commun"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4103\/NRR.NRR-D-23-01664","article-title":"Ambroxol, the cough expectorant with neuroprotective effects","volume":"19","author":"Patzwaldt K","year":"2024","unstructured":"Patzwaldt K, Castaneda-Vega S. Ambroxol, the cough expectorant with neuroprotective effects. Neural Regen Res. 2024, 19:2345-6. 10.4103\/NRR.NRR-D-23-01664","journal-title":"Neural Regen Res"},{"key":"ref24","article-title":"Uric acid plasma level and urine pH in rats treated with ambroxol","volume":"64","author":"Drewa T","year":"2007","unstructured":"Drewa T, Wolski Z, Gruszka M, Misterek B, Lysik J. Uric acid plasma level and urine pH in rats treated with ambroxol. Acta Pol Pharm. 2007, 64:565-7.","journal-title":"Acta Pol Pharm"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/bmfj.bmfj_163_17","article-title":"Effect of ambroxol on experimentally induced acute oxidative stress in the heart, kidney, and intestine in rats","volume":"35","author":"Elfouli M","year":"2018","unstructured":"Elfouli M, Said M, Emam H, Abu-raia N, Metwally M. Effect of ambroxol on experimentally induced acute oxidative stress in the heart, kidney, and intestine in rats. Benha Med J. 2018, 35:317-25. 10.4103\/bmfj.bmfj_163_17","journal-title":"Benha Med J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4149\/BLL_2022_060","article-title":"Could Ambroxol reduce cytokines in hepatic ischemia-reperfusion injury in rats?","volume":"123","author":"Gultekin C","year":"2022","unstructured":"Gultekin C, Sehirli AO, Cetinel S, Sayiner S. Could Ambroxol reduce cytokines in hepatic ischemia-reperfusion injury in rats?. Bratisl Lek Listy. 2022, 123:381-4. 10.4149\/BLL_2022_060","journal-title":"Bratisl Lek Listy"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.22038\/IJBMS.2022.64330.14148","article-title":"Does Ambroxol alleviate kidney ischemia-reperfusion injury in rats?","volume":"25","author":"G\u00fcltekin \u00c7","year":"2022","unstructured":"G\u00fcltekin \u00c7, Sayiner S, \u00c7etinel \u015e, \u015eehirli A\u00d6. Does Ambroxol alleviate kidney ischemia-reperfusion injury in rats?. Iran J Basic Med Sci. 2022, 25:1037-41. 10.22038\/IJBMS.2022.64330.14148","journal-title":"Iran J Basic Med Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2174\/1871530321666211119145230","article-title":"Ambroxol chaperone therapy for Gaucher disease type I-associated liver cirrhosis and portal hypertension: a case report","volume":"22","author":"Zhang P","year":"2022","unstructured":"Zhang P, Zheng MF, Cui SY, Zhang W, Gao RP. Ambroxol chaperone therapy for Gaucher disease type I-associated liver cirrhosis and portal hypertension: a case report. Endocr Metab Immune Disord Drug Targets. 2022, 22:658-62. 10.2174\/1871530321666211119145230","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1159\/000323622","article-title":"Effect of ambroxol on pneumonia caused by Pseudomonas aeruginosa with biofilm formation in an endotracheal intubation rat model","volume":"57","author":"Li F","year":"2011","unstructured":"Li F, Wang W, Hu L, Li L, Yu J. Effect of ambroxol on pneumonia caused by Pseudomonas aeruginosa with biofilm formation in an endotracheal intubation rat model. Chemotherapy. 2011, 57:173-80. 10.1159\/000323622","journal-title":"Chemotherapy"},{"key":"ref30","article-title":"Targeting the virulence factors of Serratia marcescens by ambroxol","volume":"76","author":"Abbas H","year":"2017","unstructured":"Abbas H, Hegazy W. Targeting the virulence factors of Serratia marcescens by ambroxol. Roum Arch Microbiol Immunol. 2017, 76:27-32.","journal-title":"Roum Arch Microbiol Immunol"},{"key":"ref31","article-title":"Ambroxol blocks swarming and swimming motilities and inhibits biofilm formation by Proteus mirabilis isolated from diabetic foot infection","volume":"3","author":"Abbas H","year":"2013","unstructured":"Abbas H. Ambroxol blocks swarming and swimming motilities and inhibits biofilm formation by Proteus mirabilis isolated from diabetic foot infection. Asian J Pharm Tech. 2013, 3:109-16.","journal-title":"Asian J Pharm Tech"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12147","article-title":"Effects of ambroxol on Candida albicans growth and biofilm formation","volume":"57","author":"Rene HD","year":"2014","unstructured":"Rene HD, Jos\u00e9 MS, Isela SN, Claudio CR. Effects of ambroxol on Candida albicans growth and biofilm formation. Mycoses. 2014, 57:228-32. 10.1111\/myc.12147","journal-title":"Mycoses"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.14744\/eej.2022.30306","article-title":"Comparison of the physicochemical properties, antimicrobial action, and cytotoxicity of ambroxol hydrochloride, N-acetylcysteine, and calcium hydroxide pastes","volume":"7","author":"Calefi PH","year":"2022","unstructured":"Calefi PH, de Azevedo Queiroz I, Alcalde M, et al.. Comparison of the physicochemical properties, antimicrobial action, and cytotoxicity of ambroxol hydrochloride, N-acetylcysteine, and calcium hydroxide pastes. Eur Endod J. 2022, 7:217-22. 10.14744\/eej.2022.30306","journal-title":"Eur Endod J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2017.00124","article-title":"Ambroxol hydrochloride combined with fluconazole reverses the resistance of Candida albicans to fluconazole","volume":"7","author":"Li X","year":"2017","unstructured":"Li X, Zhao Y, Huang X, Yu C, Yang Y, Sun S. Ambroxol hydrochloride combined with fluconazole reverses the resistance of Candida albicans to fluconazole. Front Cell Infect Microbiol. 2017, 7:124. 10.3389\/fcimb.2017.00124","journal-title":"Front Cell Infect Microbiol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2015.08.017","article-title":"Synergy of ambroxol with vancomycin in elimination of catheter-related Staphylococcus epidermidis biofilm in vitro and in vivo","volume":"21","author":"Zhang Y","year":"2015","unstructured":"Zhang Y, Fu Y, Yu J, et al.. Synergy of ambroxol with vancomycin in elimination of catheter-related Staphylococcus epidermidis biofilm in vitro and in vivo. J Infect Chemother. 2015, 21:808-15. 10.1016\/j.jiac.2015.08.017","journal-title":"J Infect Chemother"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1159\/000351107","article-title":"Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model","volume":"59","author":"Lu Q","year":"2013","unstructured":"Lu Q, Yu J, Bao L, Ran T, Zhong H. Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model. Chemotherapy. 2013, 59:51-6. 10.1159\/000351107","journal-title":"Chemotherapy"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12542","article-title":"Ambroxol inhibits mucoid conversion of Pseudomonas aeruginosa and contributes to the bactericidal activity of ciprofloxacin against mucoid P. aeruginosa biofilms","volume":"124","author":"Wang W","year":"2016","unstructured":"Wang W, Yu J, He Y, Wang Z, Li F. Ambroxol inhibits mucoid conversion of Pseudomonas aeruginosa and contributes to the bactericidal activity of ciprofloxacin against mucoid P. aeruginosa biofilms. APMIS. 2016, 124:611-8. 10.1111\/apm.12542","journal-title":"APMIS"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.809595","article-title":"Inhibition of Clostridioides difficile toxins TcdA and TcdB by ambroxol","volume":"12","author":"Heber S","year":"2021","unstructured":"Heber S, Barthold L, Baier J, et al.. Inhibition of Clostridioides difficile toxins TcdA and TcdB by ambroxol. Front Pharmacol. 2021, 12:809595. 10.3389\/fphar.2021.809595","journal-title":"Front Pharmacol"},{"key":"ref39","article-title":"Effect of azithromycin combined with ambroxol in children with Mycoplasma pneumoniae pneumonia","volume":"15","author":"Ni Y","year":"2023","unstructured":"Ni Y, Fang M, Jiang J, Lou Q, Wu L, Liu Z. Effect of azithromycin combined with ambroxol in children with Mycoplasma pneumoniae pneumonia. Am J Transl Res. 2023, 15:202-12.","journal-title":"Am J Transl Res"},{"key":"ref40","article-title":"Ambroxol and bromhexine increase antibiotic levels in the lungs","volume":"9","author":"Prasad CV","year":"2022","unstructured":"Prasad CV, Sait MAS, Ponnambalam A. Ambroxol and bromhexine increase antibiotic levels in the lungs. Eur J Mol Clin Med. 2022, 9:115-20.","journal-title":"Eur J Mol Clin Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1567-1364.2012.00792.x","article-title":"Ambroxol influences voriconazole resistance of Candida parapsilosis biofilm","volume":"12","author":"Pulcrano G","year":"2012","unstructured":"Pulcrano G, Panellis D, De Domenico G, Rossano F, Catania MR. Ambroxol influences voriconazole resistance of Candida parapsilosis biofilm. FEMS Yeast Res. 2012, 12:430-8. 10.1111\/j.1567-1364.2012.00792.x","journal-title":"FEMS Yeast Res"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004454.pub4","article-title":"Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth","volume":"12","author":"McGoldrick E","year":"2020","unstructured":"McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2020, 12:CD004454. 10.1002\/14651858.CD004454.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref43","article-title":"Prenatal and postnatal steroids and pulmonary outcomes","author":"Schmidt AF","year":"2024","unstructured":"Schmidt AF, Jobe AH. Prenatal and postnatal steroids and pulmonary outcomes. Neonatology Questions and Controversies: The Newborn Lung. Bancalari E, Keszler M, Davis PG (ed): Elsevier, Philadelphia, PA; 2024. 205-19."},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2023.09.013","article-title":"Antenatal corticosteroids: an updated assessment of anticipated benefits and potential risks","volume":"230","author":"Jobe AH","year":"2024","unstructured":"Jobe AH, Goldenberg RL, Kemp MW. Antenatal corticosteroids: an updated assessment of anticipated benefits and potential risks. Am J Obstet Gynecol. 2024, 230:330-9. 10.1016\/j.ajog.2023.09.013","journal-title":"Am J Obstet Gynecol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-020-01249-w","article-title":"Antenatal corticosteroids: a reappraisal of the drug formulation and dose","volume":"89","author":"Jobe AH","year":"2021","unstructured":"Jobe AH, Kemp M, Schmidt A, Takahashi T, Newnham J, Milad M. Antenatal corticosteroids: a reappraisal of the drug formulation and dose. Pediatr Res. 2021, 89:318-25. 10.1038\/s41390-020-01249-w","journal-title":"Pediatr Res"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-022-06724-9","article-title":"Timing of antenatal steroid administration for imminent preterm birth: results of a prospective observational study in Germany","volume":"308","author":"Humbeck C","year":"2023","unstructured":"Humbeck C, Jonassen S, Bringewatt A, Pervan M, Rody A, Bossung V. Timing of antenatal steroid administration for imminent preterm birth: results of a prospective observational study in Germany. Arch Gynecol Obstet. 2023, 308:839-47. 10.1007\/s00404-022-06724-9","journal-title":"Arch Gynecol Obstet"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911783","article-title":"Early CPAP versus surfactant in extremely preterm infants","volume":"362","author":"Finer NN","year":"2010","unstructured":"Finer NN, Carlo WA, Walsh MC, et al.. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010, 362:1970-9. 10.1056\/NEJMoa0911783","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.33331","article-title":"Association of antenatal steroid exposure at 21 to 22 weeks of gestation with neonatal survival and survival without morbidities","volume":"5","author":"Chawla S","year":"2022","unstructured":"Chawla S, Wyckoff MH, Rysavy MA, et al.. Association of antenatal steroid exposure at 21 to 22 weeks of gestation with neonatal survival and survival without morbidities. JAMA Netw Open. 2022, 5:e2233331. 10.1001\/jamanetworkopen.2022.33331","journal-title":"JAMA Netw Open"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207418","article-title":"Expectant management or early ibuprofen for patent ductus arteriosus","volume":"388","author":"Hundscheid T","year":"2023","unstructured":"Hundscheid T, Onland W, Kooi EM, et al.. Expectant management or early ibuprofen for patent ductus arteriosus. N Engl J Med. 2023, 388:980-90. 10.1056\/NEJMoa2207418","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.894526","article-title":"Partial vs. complete course of antenatal corticosteroid prophylaxis: an Italian single center retrospective study","volume":"10","author":"Xodo S","year":"2022","unstructured":"Xodo S, Trombetta G, Celante L, Pittini C, Driul L, Cagnacci A, Londero AP. Partial vs. complete course of antenatal corticosteroid prophylaxis: an Italian single center retrospective study. Front Pediatr. 2022, 10:894526. 10.3389\/fped.2022.894526","journal-title":"Front Pediatr"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3109\/14767058.2013.791273","article-title":"Neurodevelopmental outcome of extremely premature infants exposed to incomplete, no or complete antenatal steroids","volume":"26","author":"Chawla S","year":"2013","unstructured":"Chawla S, Bapat R, Pappas A, Bara R, Zidan M, Natarajan G. Neurodevelopmental outcome of extremely premature infants exposed to incomplete, no or complete antenatal steroids. J Matern Fetal Neonatal Med. 2013, 26:1542-7. 10.3109\/14767058.2013.791273","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-075835","article-title":"Association between antenatal corticosteroids and risk of serious infection in children: nationwide cohort study","volume":"382","author":"Yao TC","year":"2023","unstructured":"Yao TC, Chang SM, Wu CS, et al.. Association between antenatal corticosteroids and risk of serious infection in children: nationwide cohort study. BMJ. 2023, 382:e075835. 10.1136\/bmj-2023-075835","journal-title":"BMJ"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076035","article-title":"The proportions of term or late preterm births after exposure to early antenatal corticosteroids, and outcomes: systematic review and meta-analysis of 1.6 million infants","volume":"382","author":"Ninan K","year":"2023","unstructured":"Ninan K, Gojic A, Wang Y, Asztalos EV, Beltempo M, Murphy KE, McDonald SD. The proportions of term or late preterm births after exposure to early antenatal corticosteroids, and outcomes: systematic review and meta-analysis of 1.6 million infants. BMJ. 2023, 382:e076035. 10.1136\/bmj-2023-076035","journal-title":"BMJ"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p1722","article-title":"Antenatal corticosteroids and longer term outcomes","volume":"382","author":"Kimpton J","year":"2023","unstructured":"Kimpton J, Sammut A, Cox DJ. Antenatal corticosteroids and longer term outcomes. BMJ. 2023, 382:1722. 10.1136\/bmj.p1722","journal-title":"BMJ"},{"key":"ref55","article-title":"A pharmacokinetics study on pulmonary tropism of ambroxol on patients under thoracic surgery","volume":"13","author":"Mezzetti M","year":"1990","unstructured":"Mezzetti M. A pharmacokinetics study on pulmonary tropism of ambroxol on patients under thoracic surgery. Surg Intensive Care. 1990, 13:179-85.","journal-title":"Surg Intensive Care"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2004.07.015","article-title":"Cell-specific modulation of surfactant proteins by ambroxol treatment","volume":"203","author":"Seifart C","year":"2005","unstructured":"Seifart C, Clostermann U, Seifart U, M\u00fcller B, Vogelmeier C, von Wichert P, Fehrenbach H. Cell-specific modulation of surfactant proteins by ambroxol treatment. Toxicol Appl Pharmacol. 2005, 203:27-35. 10.1016\/j.taap.2004.07.015","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2015.10.002","article-title":"A new role for an old drug: ambroxol triggers lysosomal exocytosis via pH-dependent Ca\u00b2\u207a release from acidic Ca\u00b2\u207a stores","volume":"58","author":"Fois G","year":"2015","unstructured":"Fois G, Hobi N, Felder E, et al.. A new role for an old drug: ambroxol triggers lysosomal exocytosis via pH-dependent Ca\u00b2\u207a release from acidic Ca\u00b2\u207a stores. Cell Calcium. 2015, 58:628-37. 10.1016\/j.ceca.2015.10.002","journal-title":"Cell Calcium"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.07.043","article-title":"Oral ambroxol supplement in pregnant women induces fetal lung maturation","volume":"191","author":"Molina G","year":"2004","unstructured":"Molina G, Holguin E, Teran E. Oral ambroxol supplement in pregnant women induces fetal lung maturation. Am J Obstet Gynecol. 2004, 191:2177. 10.1016\/j.ajog.2004.07.043","journal-title":"Am J Obstet Gynecol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009708.pub2","article-title":"Ambroxol for women at risk of preterm birth for preventing neonatal respiratory distress syndrome","volume":"2014","author":"Gonzalez Garay AG","year":"2014","unstructured":"Gonzalez Garay AG, Reveiz L, Velasco Hidalgo L, Solis Galicia C. Ambroxol for women at risk of preterm birth for preventing neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2014, 2014:CD009708. 10.1002\/14651858.CD009708.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1111\/crj.12923","article-title":"Antenatal maternal medication administration in preventing respiratory distress syndrome of premature infants: a network meta-analysis","volume":"12","author":"Zhang H","year":"2018","unstructured":"Zhang H, Liu J, Liu T, Wang Y, Dai W. Antenatal maternal medication administration in preventing respiratory distress syndrome of premature infants: a network meta-analysis. Clin Respir J. 2018, 12:2480-90. 10.1111\/crj.12923","journal-title":"Clin Respir J"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw L","year":"2017","unstructured":"Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, Guyatt GH. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. 2017, 6:79. 10.1186\/s13643-017-0473-z","journal-title":"Syst Rev"},{"key":"ref62","article-title":"Network meta-analysis","author":"Harrer M","year":"2021","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Network meta-analysis. Doing Meta-Analysis With R: A Hands-On Guide. Harrer M, Cuijpers P, Furukawa TA, Ebert DD (ed): Hall\/CRC Press, Boca Raton, FL; 2021. 329-79."},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1329684","article-title":"Prevention of respiratory distress syndrome in preterm infants by antenatal ambroxol: a meta-analysis of randomized controlled trials","volume":"30","author":"Zhang ZQ","year":"2013","unstructured":"Zhang ZQ, Wu QQ, Huang XM, Lu H. Prevention of respiratory distress syndrome in preterm infants by antenatal ambroxol: a meta-analysis of randomized controlled trials. Am J Perinatol. 2013, 30:529-36. 10.1055\/s-0032-1329684","journal-title":"Am J Perinatol"},{"key":"ref64","article-title":"[Comparison of mortality and morbidity in newborns treated with ambroxol prenatally and postnatally]","volume":"66","author":"Sackey S","year":"1995","unstructured":"Sackey S, Gadzinowski J, Szymankiewicz M, Breborowicz GH, Rudnicki J, Patalan J, R\u00f3zewicki K. [Comparison of mortality and morbidity in newborns treated with ambroxol prenatally and postnatally]. Ginekol Pol. 1995, 66:439-43.","journal-title":"Ginekol Pol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1080\/10641955.2016.1190846","article-title":"Preeclampsia and preterm delivery: a population-based case-control study","volume":"35","author":"Davies EL","year":"2016","unstructured":"Davies EL, Bell JS, Bhattacharya S. Preeclampsia and preterm delivery: a population-based case-control study. Hypertens Pregnancy. 2016, 35:510-9. 10.1080\/10641955.2016.1190846","journal-title":"Hypertens Pregnancy"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26040777","article-title":"A multi-objective approach for drug repurposing in preeclampsia","volume":"26","author":"Tejera E","year":"2021","unstructured":"Tejera E, P\u00e9rez-Castillo Y, Chamorro A, Cabrera-Andrade A, Sanchez ME. A multi-objective approach for drug repurposing in preeclampsia. Molecules. 2021, 26:777. 10.3390\/molecules26040777","journal-title":"Molecules"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1515\/jpm-2014-0295","article-title":"Avoiding the prenatal programming effects of glucocorticoids: are there alternative treatments for the induction of antenatal lung maturation?","volume":"43","author":"Justus G","year":"2015","unstructured":"Justus G, Sloboda DM, Henrich W, Plagemann A, Dudenhausen JW, Braun T. Avoiding the prenatal programming effects of glucocorticoids: are there alternative treatments for the induction of antenatal lung maturation?. J Perinat Med. 2015, 43:503-23. 10.1515\/jpm-2014-0295","journal-title":"J Perinat Med"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1268236","article-title":"The effect of low to moderate patient volume on very low-birth-weight outcomes in a level III-B neonatal intensive care unit","volume":"28","author":"Al-Abdi S","year":"2011","unstructured":"Al-Abdi S, Abou Mehrem A, Dabelah K, Al-Aghbari M, Al-Aamri M. The effect of low to moderate patient volume on very low-birth-weight outcomes in a level III-B neonatal intensive care unit. Am J Perinatol. 2011, 28:219-26. 10.1055\/s-0030-1268236","journal-title":"Am J Perinatol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1159\/000528914","article-title":"European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 update","volume":"120","author":"Sweet DG","year":"2023","unstructured":"Sweet DG, Carnielli VP, Greisen G, et al.. European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 update. Neonatology. 2023, 120:3-23. 10.1159\/000528914","journal-title":"Neonatology"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5980","article-title":"Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis","volume":"347","author":"Schm\u00f6lzer GM","year":"2013","unstructured":"Schm\u00f6lzer GM, Kumar M, Pichler G, Aziz K, O'Reilly M, Cheung PY. Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis. BMJ. 2013, 347:f5980. 10.1136\/bmj.f5980","journal-title":"BMJ"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.semperi.2024.151885","article-title":"Non-invasive versus invasive respiratory support in preterm infants","volume":"48","author":"Manley BJ","year":"2024","unstructured":"Manley BJ, Cripps E, Dargaville PA. Non-invasive versus invasive respiratory support in preterm infants. Semin Perinatol. 2024, 48:151885. 10.1016\/j.semperi.2024.151885","journal-title":"Semin Perinatol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001456.pub2","article-title":"Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome","volume":"11","author":"Bahadue FL","year":"2012","unstructured":"Bahadue FL, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2012, 11:CD001456. 10.1002\/14651858.CD001456.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-065373","article-title":"Early bubble CPAP protocol implementation and rates of death or severe BPD","volume":"154","author":"de Carvalho Nunes G","year":"2024","unstructured":"de Carvalho Nunes G, Barbosa de Oliveira C, Zeid M, et al.. Early bubble CPAP protocol implementation and rates of death or severe BPD. Pediatrics. 2024, 154:e2023065373. 10.1542\/peds.2023-065373","journal-title":"Pediatrics"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072788","article-title":"Nasal CPAP or intubation at birth for very preterm infants","volume":"358","author":"Morley CJ","year":"2008","unstructured":"Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet JM, Carlin JB. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med. 2008, 358:700-8. 10.1056\/NEJMoa072788","journal-title":"N Engl J Med"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011672.pub2","article-title":"Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome","volume":"5","author":"Abdel-Latif ME","year":"2021","unstructured":"Abdel-Latif ME, Davis PG, Wheeler KI, De Paoli AG, Dargaville PA. Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database Syst Rev. 2021, 5:CD011672. 10.1002\/14651858.CD011672.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jped.2023.05.008","article-title":"Less invasive surfactant administration versus intubation-surfactant-extubation in the treatment of neonatal respiratory distress syndrome: a systematic review and meta-analyses","volume":"100","author":"Silveira RC","year":"2024","unstructured":"Silveira RC, Panceri C, Mun\u00f5z NP, Carvalho MB, Fraga AC, Procianoy RS. Less invasive surfactant administration versus intubation-surfactant-extubation in the treatment of neonatal respiratory distress syndrome: a systematic review and meta-analyses. J Pediatr (Rio J). 2024, 100:8-24. 10.1016\/j.jped.2023.05.008","journal-title":"J Pediatr (Rio J)"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.siny.2023.101497","article-title":"Surfactant delivery by aerosol inhalation - past, present, and future","volume":"28","author":"Guthrie SO","year":"2023","unstructured":"Guthrie SO, Pillow JJ, Cummings JJ. Surfactant delivery by aerosol inhalation - past, present, and future. Semin Fetal Neonatal Med. 2023, 28:101497. 10.1016\/j.siny.2023.101497","journal-title":"Semin Fetal Neonatal Med"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-052504","article-title":"Surfactant nebulization to prevent intubation in preterm infants: a systematic review and meta-analysis","volume":"148","author":"Gaertner VD","year":"2021","unstructured":"Gaertner VD, Thomann J, Bassler D, R\u00fcegger CM. Surfactant nebulization to prevent intubation in preterm infants: a systematic review and meta-analysis. Pediatrics. 2021, 148:e2021052504. 10.1542\/peds.2021-052504","journal-title":"Pediatrics"},{"key":"ref79","article-title":"[Ambroxol for the prevention of respiratory distress syndrome in preterm infants: a meta analysis]","volume":"12","author":"Zhang ZQ","year":"2010","unstructured":"Zhang ZQ, Huang XM, Lu H. [Ambroxol for the prevention of respiratory distress syndrome in preterm infants: a meta analysis]. Zhongguo Dang Dai Er Ke Za Zhi. 2010, 12:858-63.","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604.ch6","article-title":"Choosing effect measures and computing estimates of effect","author":"Higgins JP","year":"2019","unstructured":"Higgins JP, Li T, Deeks JJ. Choosing effect measures and computing estimates of effect. Cochrane Handbook for Systematic Reviews of Interventions. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (ed): John Wiley & Sons, Chichester, UK; 2019. 143-76. 10.1002\/9781119536604.ch6"},{"key":"ref81","article-title":"Evaluation of the role of postnatal ambroxol in the prevention and treatment of respiratory distress syndrome in preterm neonates","volume":"6","author":"Elsayed HF","year":"2006","unstructured":"Elsayed HF, Elkhaiouby MI, Elsharkawey SM, Elnemr MA. Evaluation of the role of postnatal ambroxol in the prevention and treatment of respiratory distress syndrome in preterm neonates. Sultan Qaboos Univ Med J. 2006, 6:41-6.","journal-title":"Sultan Qaboos Univ Med J"},{"key":"ref82","article-title":"A systematic review of ambroxol administered intravenously for infant hyaline membrane disease","volume":"47","author":"Chen XH","year":"2012","unstructured":"Chen XH. A systematic review of ambroxol administered intravenously for infant hyaline membrane disease. Chin Pharm J. 2012, 47:771-5.","journal-title":"Chin Pharm J"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.21608\/anj.2022.121976.1046","article-title":"Evaluation of the role of ambroxol in treatment of respiratory distress syndrome: a prospective randomized - controlled trial","volume":"4","author":"Hassan A-eA","year":"2022","unstructured":"Hassan A-eA, Ezzat M, Elmorsy WA. Evaluation of the role of ambroxol in treatment of respiratory distress syndrome: a prospective randomized - controlled trial. Ann Neonatol J. 2022, 4:187-203. 10.21608\/anj.2022.121976.1046","journal-title":"Ann Neonatol J"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.7615","article-title":"Efficacy of pulmonary surfactant combined with high-dose ambroxol hydrochloride in the treatment of neonatal respiratory distress syndrome","volume":"18","author":"Xiang J","year":"2019","unstructured":"Xiang J, Wang P. Efficacy of pulmonary surfactant combined with high-dose ambroxol hydrochloride in the treatment of neonatal respiratory distress syndrome. Exp Ther Med. 2019, 18:654-8. 10.3892\/etm.2019.7615","journal-title":"Exp Ther Med"},{"key":"ref85","article-title":"Clinical observation of ambroxol hydrochloride in the treatment of neonatal respiratory distress syndrome","volume":"12","author":"Shi Z","year":"2016","unstructured":"Shi Z, Qiu L, Chen Y. Clinical observation of ambroxol hydrochloride in the treatment of neonatal respiratory distress syndrome. China Pharm. 2016, 12:3279-81.","journal-title":"China Pharm"},{"key":"ref86","article-title":"[Clinical observation of ambroxol combined with caffeine in treatment of neonatal respiratory distress syndrome]","volume":"34","author":"Sun RX","year":"2019","unstructured":"Sun RX, Jiang H, Li XZ, Zhang NM, Hao LX. [Clinical observation of ambroxol combined with caffeine in treatment of neonatal respiratory distress syndrome]. Drugs Clinic. 2019, 34:3008-11.","journal-title":"Drugs Clinic"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.7619\/jcmp.20223818","article-title":"[Effect of different non-invasive ventilation modes combined with ambroxol in the treatment of respiratory distress syndrome in premature infants]","volume":"27","author":"Yanling Z","year":"2023","unstructured":"Yanling Z, Jian L, Yiying F, Hua W. [Effect of different non-invasive ventilation modes combined with ambroxol in the treatment of respiratory distress syndrome in premature infants]. J Clin Med Pract. 2023, 27:55-8. 10.7619\/jcmp.20223818","journal-title":"J Clin Med Pract"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202306_32627","article-title":"Therapeutic effect of micropump intravenous infusion of ambroxol hydrochloride on respiratory distress syndrome in premature infants","volume":"27","author":"Xu JS","year":"2023","unstructured":"Xu JS, Li BH, Xu YQ, Li J, Lin Y. Therapeutic effect of micropump intravenous infusion of ambroxol hydrochloride on respiratory distress syndrome in premature infants. Eur Rev Med Pharmacol Sci. 2023, 27:5105-18. 10.26355\/eurrev_202306_32627","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref89","article-title":"Comparison of therapeutic effects of budesonide and ambroxol combined with bovine pulmonary surfactant on neonatal respiratory distress syndrome","volume":"13","author":"Shi L","year":"2020","unstructured":"Shi L, Shan G, Zhang X, Zhang B, Zhang A, Liu Z. Comparison of therapeutic effects of budesonide and ambroxol combined with bovine pulmonary surfactant on neonatal respiratory distress syndrome. Int J Clin Exp Med. 2020, 13:5754-62.","journal-title":"Int J Clin Exp Med"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3978","article-title":"Different ventilation modes combined with ambroxol in the treatment of respiratory distress syndrome in premature infants","volume":"13","author":"Zhou B","year":"2017","unstructured":"Zhou B, Zhai JF, Wu JB, Jin B, Zhang YY. Different ventilation modes combined with ambroxol in the treatment of respiratory distress syndrome in premature infants. Exp Ther Med. 2017, 13:629-33. 10.3892\/etm.2016.3978","journal-title":"Exp Ther Med"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.4172\/2167-0897.1000216","article-title":"Use of ambroxol and treatment of klebsiella ozaenae in extremely low birth weight preterm: case report and literature review","volume":"5","author":"Yonglin L","year":"2016","unstructured":"Yonglin L, Yanmei Q, Zhongming Y, Xiaopu Z, Shamsi B. Use of ambroxol and treatment of klebsiella ozaenae in extremely low birth weight preterm: case report and literature review. J Neonatal Biol. 2016, 5:1-4. 10.4172\/2167-0897.1000216","journal-title":"J Neonatal Biol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013271.pub2","article-title":"Corticosteroids for the prevention and treatment of bronchopulmonary dysplasia: an overview of systematic reviews","volume":"4","author":"van de Loo M","year":"2024","unstructured":"van de Loo M, van Kaam A, Offringa M, Doyle LW, Cooper C, Onland W. Corticosteroids for the prevention and treatment of bronchopulmonary dysplasia: an overview of systematic reviews. Cochrane Database Syst Rev. 2024, 4:CD013271. 10.1002\/14651858.CD013271.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.resmer.2024.101096","article-title":"Efficacy and safety of different inhaled corticosteroids for bronchopulmonary dysplasia prevention in preterm infants: a systematic review and meta-analysis","volume":"85","author":"Zhang M","year":"2024","unstructured":"Zhang M, Zhang W, Liao H. Efficacy and safety of different inhaled corticosteroids for bronchopulmonary dysplasia prevention in preterm infants: a systematic review and meta-analysis. Respir Med Res. 2024, 85:101096. 10.1016\/j.resmer.2024.101096","journal-title":"Respir Med Res"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1159\/000530128","article-title":"Trends, characteristic, and outcomes of preterm infants who received postnatal corticosteroid: a cohort study from 7 high-income countries","volume":"120","author":"Parikh S","year":"2023","unstructured":"Parikh S, Reichman B, Kusuda S, et al.. Trends, characteristic, and outcomes of preterm infants who received postnatal corticosteroid: a cohort study from 7 high-income countries. Neonatology. 2023, 120:517-26. 10.1159\/000530128","journal-title":"Neonatology"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.1999.0751","article-title":"Effect of early ambroxol treatment on lung functions in mechanically ventilated preterm newborns who subsequently developed a bronchopulmonary dysplasia (BPD)","volume":"94","author":"Schmalisch G","year":"2000","unstructured":"Schmalisch G, Wauer RR, B\u00f6hme B. Effect of early ambroxol treatment on lung functions in mechanically ventilated preterm newborns who subsequently developed a bronchopulmonary dysplasia (BPD). Respir Med. 2000, 94:378-84. 10.1053\/rmed.1999.0751","journal-title":"Respir Med"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1891\/0730-0832.31.2.89","article-title":"Neonatal care in a Japanese NICU: notes based on a site visit","volume":"31","author":"Chirinian N","year":"2012","unstructured":"Chirinian N, Uji A, Isayama T, Shah V. Neonatal care in a Japanese NICU: notes based on a site visit. Neonatal Netw. 2012, 31:89-96. 10.1891\/0730-0832.31.2.89","journal-title":"Neonatal Netw"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201906_18092","article-title":"Ambroxol alleviates ventilator-induced lung injury by inhibiting c-Jun expression","volume":"23","author":"Cao DW","year":"2019","unstructured":"Cao DW, Hou MX, Zhang XR. Ambroxol alleviates ventilator-induced lung injury by inhibiting c-Jun expression. Eur Rev Med Pharmacol Sci. 2019, 23:5004-11. 10.26355\/eurrev_201906_18092","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.2165\/00128072-200305070-00004","article-title":"Current perspectives on the prevention and management of chronic lung disease in preterm infants","volume":"5","author":"Shah PS","year":"2003","unstructured":"Shah PS. Current perspectives on the prevention and management of chronic lung disease in preterm infants. Paediatr Drugs. 2003, 5:463-80. 10.2165\/00128072-200305070-00004","journal-title":"Paediatr Drugs"},{"key":"ref99","article-title":"A systematic review of ambroxol hydrochloride in patients with meconium aspiration syndrome","volume":"24","author":"Yin X","year":"2012","unstructured":"Yin X. A systematic review of ambroxol hydrochloride in patients with meconium aspiration syndrome. Chin Pharm J. 2012, 24:776-81.","journal-title":"Chin Pharm J"},{"key":"ref100","article-title":"Clinical effect of different administration routes of ambroxol combined with low-dose dexamethasone on treatment of neonates with meconium aspiration pneumonia","volume":"28","author":"Jin WM","year":"2018","unstructured":"Jin WM, Huang YM, Yang XL, Zheng G, Chen X. Clinical effect of different administration routes of ambroxol combined with low-dose dexamethasone on treatment of neonates with meconium aspiration pneumonia. Chin J Nosocomiol. 2018, 28:1548-51.","journal-title":"Chin J Nosocomiol"},{"key":"ref101","article-title":"Clinical effect of budesonide combined with ambroxol in the treatment of neonatal aspiration pneumonia","volume":"6","author":"Yao H","year":"2017","unstructured":"Yao H. Clinical effect of budesonide combined with ambroxol in the treatment of neonatal aspiration pneumonia. Chinese J Biochem Pharm. 2017, 6:280-2.","journal-title":"Chinese J Biochem Pharm"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8469487","article-title":"Machine learning algorithm-based analysis of efficacy of pulmonary surfactant combined with mucosolvan in meconium aspiration syndrome of newborns through ultrasonic images","volume":"2021","author":"Ji Y","year":"2021","unstructured":"Ji Y, Lou W, Ji J. Machine learning algorithm-based analysis of efficacy of pulmonary surfactant combined with mucosolvan in meconium aspiration syndrome of newborns through ultrasonic images. Sci Program. 2021, 2021:8469487. 10.1155\/2021\/8469487","journal-title":"Sci Program"},{"key":"ref103","article-title":"Efficacy of ambroxol combined with imipenem on severe neonatal pneumonia","volume":"12","author":"Zhang X","year":"2014","unstructured":"Zhang X, Zhou W. Efficacy of ambroxol combined with imipenem on severe neonatal pneumonia. Chinese J Primary Med Pharm. 2014, 12:3136-7.","journal-title":"Chinese J Primary Med Pharm"},{"key":"ref104","article-title":"Clinical study of curative effect of ambroxol on the treatment of infectious pneumonia in the newborn","volume":"12","author":"Yao X","year":"2011","unstructured":"Yao X. Clinical study of curative effect of ambroxol on the treatment of infectious pneumonia in the newborn. Chinese J Primary Med Pharm. 2011, 12:769-70.","journal-title":"Chinese J Primary Med Pharm"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21105","article-title":"Meta-analysis of the efficacy of budesonide and ambroxol hydrochloride inhalation in children with pneumonia and their effects on inflammatory response","volume":"9","author":"Shen H","year":"2023","unstructured":"Shen H, Zhao X, Xu L. Meta-analysis of the efficacy of budesonide and ambroxol hydrochloride inhalation in children with pneumonia and their effects on inflammatory response. Heliyon. 2023, 9:e21105. 10.1016\/j.heliyon.2023.e21105","journal-title":"Heliyon"},{"key":"ref106","article-title":"The effect of ambroxol on the vascular reactivity in the rabbit","volume":"99","author":"Hol\u00e9cyov\u00e1 A","year":"1998","unstructured":"Hol\u00e9cyov\u00e1 A, Kriska M. The effect of ambroxol on the vascular reactivity in the rabbit. Bratisl Lek Listy. 1998, 99:99-103.","journal-title":"Bratisl Lek Listy"},{"key":"ref107","article-title":"Mechanisms regulating closure of the ductus arteriosus","author":"Clyman RI","year":"2021","unstructured":"Clyman RI. Mechanisms regulating closure of the ductus arteriosus. Fetal and Neonatal Physiology. Polin RA, Abman SH, Rowitch DH, Benitz W (ed): Elsevier, Philadelphia, PA; 2021. 1:553-64."},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00516","article-title":"Molecular and mechanical mechanisms regulating ductus arteriosus closure in preterm infants","volume":"8","author":"Oval\u0131 F","year":"2020","unstructured":"Oval\u0131 F. Molecular and mechanical mechanisms regulating ductus arteriosus closure in preterm infants. Front Pediatr. 2020, 8:516. 10.3389\/fped.2020.00516","journal-title":"Front Pediatr"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.300.2.629","article-title":"Depressant effect of ambroxol on stimulated functional responses and cell death in rat alveolar macrophages exposed to silica in vitro","volume":"300","author":"Kim YK","year":"2002","unstructured":"Kim YK, Jang YY, Han ES, Lee CS. Depressant effect of ambroxol on stimulated functional responses and cell death in rat alveolar macrophages exposed to silica in vitro. J Pharmacol Exp Ther. 2002, 300:629-37. 10.1124\/jpet.300.2.629","journal-title":"J Pharmacol Exp Ther"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/s0014-2999(00)00739-1","article-title":"Ambroxol as an inhibitor of nitric oxide-dependent activation of soluble guanylate cyclase","volume":"407","author":"Severina IS","year":"2000","unstructured":"Severina IS, Bussygina OG, Pyatakova NV, Khropov YV, Krasnoperov RA. Ambroxol as an inhibitor of nitric oxide-dependent activation of soluble guanylate cyclase. Eur J Pharmacol. 2000, 407:61-4. 10.1016\/s0014-2999(00)00739-1","journal-title":"Eur J Pharmacol"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0773.2002.910309.x","article-title":"Ambroxol inhibits peroxynitrite-induced damage of alpha1-antiproteinase and free radical production in activated phagocytic cells","volume":"91","author":"Lee CS","year":"2002","unstructured":"Lee CS, Jang YY, Song JS, Song JH, Han ES. Ambroxol inhibits peroxynitrite-induced damage of alpha1-antiproteinase and free radical production in activated phagocytic cells. Pharmacol Toxicol. 2002, 91:140-9. 10.1034\/j.1600-0773.2002.910309.x","journal-title":"Pharmacol Toxicol"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0773.2003.920407.x","article-title":"Depressant effects of ambroxol and erdosteine on cytokine synthesis, granule enzyme release, and free radical production in rat alveolar macrophages activated by lipopolysaccharide","volume":"92","author":"Jang YY","year":"2003","unstructured":"Jang YY, Song JH, Shin YK, Han ES, Lee CS. Depressant effects of ambroxol and erdosteine on cytokine synthesis, granule enzyme release, and free radical production in rat alveolar macrophages activated by lipopolysaccharide. Pharmacol Toxicol. 2003, 92:173-9. 10.1034\/j.1600-0773.2003.920407.x","journal-title":"Pharmacol Toxicol"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1016\/s0049-3848(01)00412-1","article-title":"Adenosine increases human platelet levels of cGMP through nitric oxide: possible role in its antiaggregating effect","volume":"105","author":"Anfossi G","year":"2002","unstructured":"Anfossi G, Russo I, Massucco P, Mattiello L, Cavalot F, Balbo A, Trovati M. Adenosine increases human platelet levels of cGMP through nitric oxide: possible role in its antiaggregating effect. Thromb Res. 2002, 105:71-8. 10.1016\/s0049-3848(01)00412-1","journal-title":"Thromb Res"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/pxab085","article-title":"Management of the patent ductus arteriosus in preterm infants","volume":"27","author":"Mitra S","year":"2022","unstructured":"Mitra S, Weisz D, Jain A, Jong G'. Management of the patent ductus arteriosus in preterm infants. Paediatr Child Health. 2022, 27:63-4. 10.1093\/pch\/pxab085","journal-title":"Paediatr Child Health"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1038\/s41372-024-02052-9","article-title":"Procedural closure of the patent ductus arteriosus in preterm infants: a clinical practice guideline [in press]","author":"Mitra S","year":"2024","unstructured":"Mitra S, Bischoff AR, Sathanandam S, Lakshminrusimha S, McNamara PJ. Procedural closure of the patent ductus arteriosus in preterm infants: a clinical practice guideline [in press]. J Perinatol. 2024, 10.1038\/s41372-024-02052-9","journal-title":"J Perinatol"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-022-02888-y","article-title":"Dual therapy vs. monotherapy for the patent ductus arteriosus: a systematic review","volume":"43","author":"Hammerman C","year":"2022","unstructured":"Hammerman C, Bin-Nun A, Abdaljalil H, et al.. Dual therapy vs. monotherapy for the patent ductus arteriosus: a systematic review. Pediatr Cardiol. 2022, 43:935-42. 10.1007\/s00246-022-02888-y","journal-title":"Pediatr Cardiol"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1038\/s41372-022-01500-8","article-title":"Dual medication therapy (acetaminophen and ibuprofen) for the management of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis","volume":"42","author":"Shah SD","year":"2022","unstructured":"Shah SD, Makker K, Zhang M, Harnett S, Aziz KB, Hudak ML. Dual medication therapy (acetaminophen and ibuprofen) for the management of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. J Perinatol. 2022, 42:1654-61. 10.1038\/s41372-022-01500-8","journal-title":"J Perinatol"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.04.017","article-title":"Ten common questions (and their answers) about off-label drug use","volume":"87","author":"Wittich CM","year":"2012","unstructured":"Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 2012, 87:982-90. 10.1016\/j.mayocp.2012.04.017","journal-title":"Mayo Clin Proc"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-065905","article-title":"Transcatheter and surgical ductus arteriosus closure in very low birth weight infants: 2018-2022","volume":"154","author":"Leahy BF","year":"2024","unstructured":"Leahy BF, Edwards EM, Ehret DE, Soll RF, Yeager SB, Flyer JN. Transcatheter and surgical ductus arteriosus closure in very low birth weight infants: 2018-2022. Pediatrics. 2024, 154:e2024065905. 10.1542\/peds.2024-065905","journal-title":"Pediatrics"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1017\/S1047951123004353","article-title":"Percutaneous closure of patent ductus arteriosus versus surgical treatment in low-birth-weight preterms: a systematic review and meta-analysis","volume":"34","author":"Melchior CD","year":"2024","unstructured":"Melchior CD, Neves GR, de Oliveira BL, Toguchi AC, Lopes JC, Pavione MA, Enr\u00edquez SK. Percutaneous closure of patent ductus arteriosus versus surgical treatment in low-birth-weight preterms: a systematic review and meta-analysis. Cardiol Young. 2024, 34:705-12. 10.1017\/S1047951123004353","journal-title":"Cardiol Young"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2024.114052","article-title":"Cardiorespiratory instability after percutaneous patent ductus arteriosus closure: a multicenter cohort study","volume":"271","author":"Bischoff AR","year":"2024","unstructured":"Bischoff AR, Backes CH, Rivera B, et al.. Cardiorespiratory instability after percutaneous patent ductus arteriosus closure: a multicenter cohort study. J Pediatr. 2024, 271:114052. 10.1016\/j.jpeds.2024.114052","journal-title":"J Pediatr"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1080\/14767058.2018.1481043","article-title":"The effect of combined therapy for treatment of monotherapy-resistant PDA in preterm infants","volume":"32","author":"Yurttutan S","year":"2019","unstructured":"Yurttutan S, Bozkaya A, H\u00fcdayioglu F, Oncel MY. The effect of combined therapy for treatment of monotherapy-resistant PDA in preterm infants. J Matern Fetal Neonatal Med. 2019, 32:3662-5. 10.1080\/14767058.2018.1481043","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.14734\/PN.2024.35.2.52","article-title":"Combination therapy with acetaminophen and ibuprofen for patent ductus arteriosus in extremely preterm infants: a retrospective study in South Korea","volume":"35","author":"Kim EJ","year":"2024","unstructured":"Kim EJ, Cho HJ, Beak GY, Jin W, Son DW. Combination therapy with acetaminophen and ibuprofen for patent ductus arteriosus in extremely preterm infants: a retrospective study in South Korea. Perinatology. 2024, 35:52-60. 10.14734\/PN.2024.35.2.52","journal-title":"Perinatology"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305582","article-title":"Trial of selective early treatment of patent ductus arteriosus with ibuprofen","volume":"390","author":"Gupta S","year":"2024","unstructured":"Gupta S, Subhedar NV, Bell JL, et al.. Trial of selective early treatment of patent ductus arteriosus with ibuprofen. N Engl J Med. 2024, 390:314-25. 10.1056\/NEJMoa2305582","journal-title":"N Engl J Med"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-065056","article-title":"Acetaminophen for patent ductus arteriosus and risk of mortality and pulmonary morbidity","volume":"154","author":"Jensen EA","year":"2024","unstructured":"Jensen EA, DeMauro SB, Rysavy MA, et al.. Acetaminophen for patent ductus arteriosus and risk of mortality and pulmonary morbidity. Pediatrics. 2024, 154:e2023065056. 10.1542\/peds.2023-065056","journal-title":"Pediatrics"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106283442602","article-title":"Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants","volume":"344","author":"Schmidt B","year":"2001","unstructured":"Schmidt B, Davis P, Moddemann D, et al.. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001, 344:1966-72. 10.1056\/NEJM200106283442602","journal-title":"N Engl J Med"},{"key":"ref127","article-title":"Advanced Therapeutics in Pain Medicine","author":"Swidan S","year":"2021","unstructured":"Swidan S, Bennett M. Advanced Therapeutics in Pain Medicine. CRC Press, Taylor & Francis Group, Boca Raton, FL; 2021."},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002693","article-title":"Ambroxol for neuropathic pain: hiding in plain sight?","volume":"164","author":"Russo MA","year":"2023","unstructured":"Russo MA, Baron R, Dickenson AH, Kern KU, Santarelli DM. Ambroxol for neuropathic pain: hiding in plain sight?. Pain. 2023, 164:3-13. 10.1097\/j.pain.0000000000002693","journal-title":"Pain"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S139223","article-title":"Ambroxol for the treatment of fibromyalgia: science or fiction?","volume":"10","author":"Kern KU","year":"2017","unstructured":"Kern KU, Schwickert M. Ambroxol for the treatment of fibromyalgia: science or fiction?. J Pain Res. 2017, 10:1905-29. 10.2147\/JPR.S139223","journal-title":"J Pain Res"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2018-0048","article-title":"Successful treatment of complex regional pain syndrome with topical ambroxol: a case series","volume":"8","author":"Maih\u00f6fner C","year":"2018","unstructured":"Maih\u00f6fner C, Schneider S, Bialas P, Gockel H, Beer KG, Bartels M, Kern KU. Successful treatment of complex regional pain syndrome with topical ambroxol: a case series. Pain Manag. 2018, 8:427-36. 10.2217\/pmt-2018-0048","journal-title":"Pain Manag"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.757","article-title":"Epidemiology of painful procedures performed in neonates: a systematic review of observational studies","volume":"20","author":"Cruz MD","year":"2016","unstructured":"Cruz MD, Fernandes AM, Oliveira CR. Epidemiology of painful procedures performed in neonates: a systematic review of observational studies. Eur J Pain. 2016, 20:489-98. 10.1002\/ejp.757","journal-title":"Eur J Pain"},{"key":"ref132","article-title":"Volpe's Neurology of the Newborn E-Book","author":"Volpe JJ","year":"2024","unstructured":"Volpe JJ, Inder TE. Volpe's Neurology of the Newborn E-Book. Elsevier Health Sciences, Philadelphia, PA; 2024."},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.113764","article-title":"Protein unbound pharmacokinetics of ambroxol in the blood and brains of rats and the interaction of ambroxol with Polygala tenuifolia by multiple microdialysis","volume":"269","author":"Yang CN","year":"2021","unstructured":"Yang CN, Peng WY, Lin LC, Tsai TH. Protein unbound pharmacokinetics of ambroxol in the blood and brains of rats and the interaction of ambroxol with Polygala tenuifolia by multiple microdialysis. J Ethnopharmacol. 2021, 269:113764. 10.1016\/j.jep.2020.113764","journal-title":"J Ethnopharmacol"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2013.00076","article-title":"The serotonin 5-HT3 receptor: a novel neurodevelopmental target","volume":"7","author":"Engel M","year":"2013","unstructured":"Engel M, Smidt MP, van Hooft JA. The serotonin 5-HT3 receptor: a novel neurodevelopmental target. Front Cell Neurosci. 2013, 7:76. 10.3389\/fncel.2013.00076","journal-title":"Front Cell Neurosci"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2018.02.002","article-title":"In vitro pharmacology of ambroxol: potential serotonergic sites of action","volume":"197","author":"Hull JD","year":"2018","unstructured":"Hull JD, Lyon RA. In vitro pharmacology of ambroxol: potential serotonergic sites of action. Life Sci. 2018, 197:67-72. 10.1016\/j.lfs.2018.02.002","journal-title":"Life Sci"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19r12965","article-title":"Long-term effects of intrauterine exposure to antidepressants on physical, neurodevelopmental, and psychiatric outcomes: a systematic review","volume":"81","author":"Rommel AS","year":"2020","unstructured":"Rommel AS, Bergink V, Liu X, Munk-Olsen T, Molenaar NM. Long-term effects of intrauterine exposure to antidepressants on physical, neurodevelopmental, and psychiatric outcomes: a systematic review. J Clin Psychiatry. 2020, 81:19r12965. 10.4088\/JCP.19r12965","journal-title":"J Clin Psychiatry"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsc.2023.10.009","article-title":"Intrauterine exposure to antidepressants or maternal depressive symptoms and offspring brain white matter trajectories from late childhood to adolescence","volume":"9","author":"Koc D","year":"2024","unstructured":"Koc D, El Marroun H, Stricker BH, Muetzel RL, Tiemeier H. Intrauterine exposure to antidepressants or maternal depressive symptoms and offspring brain white matter trajectories from late childhood to adolescence. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024, 9:217-26. 10.1016\/j.bpsc.2023.10.009","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2019.04.002","article-title":"Neurodevelopmental outcomes of extremely preterm infants in southern China: a multicenter study","volume":"133","author":"Li Y","year":"2019","unstructured":"Li Y, Meng DH, Wei QF, et al.. Neurodevelopmental outcomes of extremely preterm infants in southern China: a multicenter study. Early Hum Dev. 2019, 133:5-10. 10.1016\/j.earlhumdev.2019.04.002","journal-title":"Early Hum Dev"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1177\/03000605211028026","article-title":"Global prevalence of long-term neurodevelopmental impairment following extremely preterm birth: a systematic literature review","volume":"49","author":"Sarda SP","year":"2021","unstructured":"Sarda SP, Sarri G, Siffel C. Global prevalence of long-term neurodevelopmental impairment following extremely preterm birth: a systematic literature review. J Int Med Res. 2021, 49:3000605211028026. 10.1177\/03000605211028026","journal-title":"J Int Med Res"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1584138","article-title":"A new IVH scoring system based on laterality enhances prediction of neurodevelopmental outcomes at 3 years age in premature infants","volume":"34","author":"Al-Mouqdad M","year":"2017","unstructured":"Al-Mouqdad M, Al-Abdi S, Scott JN, et al.. A new IVH scoring system based on laterality enhances prediction of neurodevelopmental outcomes at 3 years age in premature infants. Am J Perinatol. 2017, 34:44-50. 10.1055\/s-0036-1584138","journal-title":"Am J Perinatol"},{"key":"ref141","article-title":"A severity score for intraventricular hemorrhage in preterm neonates","volume":"32","author":"Al-Abdi SY","year":"2011","unstructured":"Al-Abdi SY. A severity score for intraventricular hemorrhage in preterm neonates. Saudi Med J. 2011, 32:1313-4.","journal-title":"Saudi Med J"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.4103\/2249-4847.134674","article-title":"A systematic review and meta-analysis of the timing of early intraventricular hemorrhage in preterm neonates: clinical and research implications","volume":"3","author":"Al-Abdi SY","year":"2014","unstructured":"Al-Abdi SY, Al-Aamri MA. A systematic review and meta-analysis of the timing of early intraventricular hemorrhage in preterm neonates: clinical and research implications. J Clin Neonatol. 2014, 3:76-88. 10.4103\/2249-4847.134674","journal-title":"J Clin Neonatol"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2021.07.063","article-title":"Timing of intraventricular hemorrhage in preterm neonates","volume":"239","author":"Al-Abdi SY","year":"2021","unstructured":"Al-Abdi SY, Al-Aamri MA. Timing of intraventricular hemorrhage in preterm neonates. J Pediatr. 2021, 239:248. 10.1016\/j.jpeds.2021.07.063","journal-title":"J Pediatr"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.3233\/NPM-1781","article-title":"Selective prophylactic solvent-detergent plasma and cryoprecipitate transfusion to prevent intraventricular hemorrhage in extreme preterm infants: a case-historical control","volume":"11","author":"Al-Abdi S","year":"2018","unstructured":"Al-Abdi S, Dabelah K, Mousa T, Ul-Rahman N, Matar K, Sheta A, Algirim H. Selective prophylactic solvent-detergent plasma and cryoprecipitate transfusion to prevent intraventricular hemorrhage in extreme preterm infants: a case-historical control. J Neonatal Perinatal Med. 2018, 11:241-8. 10.3233\/NPM-1781","journal-title":"J Neonatal Perinatal Med"},{"key":"ref145","article-title":"Pilot-randomized study on intraventricular hemorrhage with midline versus lateral head positions","volume":"32","author":"Al-Abdi SY","year":"2011","unstructured":"Al-Abdi SY, Nojoom MS, Alshaalan HM, Al-Aamri MA. Pilot-randomized study on intraventricular hemorrhage with midline versus lateral head positions. Saudi Med J. 2011, 32:420-1.","journal-title":"Saudi Med J"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7793.2000.00619.x","article-title":"Effects of betamethasone administration to the fetal sheep in late gestation on fetal cerebral blood flow","volume":"528","author":"Schwab M","year":"2000","unstructured":"Schwab M, Roedel M, Anwar MA, et al.. Effects of betamethasone administration to the fetal sheep in late gestation on fetal cerebral blood flow. J Physiol. 2000, 528:619-32. 10.1111\/j.1469-7793.2000.00619.x","journal-title":"J Physiol"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1907423","article-title":"A randomized trial of erythropoietin for neuroprotection in preterm infants","volume":"382","author":"Juul SE","year":"2020","unstructured":"Juul SE, Comstock BA, Wadhawan R, et al.. A randomized trial of erythropoietin for neuroprotection in preterm infants. N Engl J Med. 2020, 382:233-43. 10.1056\/NEJMoa1907423","journal-title":"N Engl J Med"},{"key":"ref148","article-title":"Neurotransmission in the central nervous system","author":"Free RB","year":"2023","unstructured":"Free RB, Underhill SM, Amara SG, Sibley DR. Neurotransmission in the central nervous system. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. Brunton LL, Knollmann BC (ed): McGraw-Hill Education, New York, NY; 2023. 305-26."},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2020.596039","article-title":"Ambroxol upregulates glucocerebrosidase expression to promote neural stem cells differentiation into neurons through Wnt\/\u03b2-catenin pathway after ischemic stroke","volume":"13","author":"Ge H","year":"2020","unstructured":"Ge H, Zhang C, Yang Y, et al.. Ambroxol upregulates glucocerebrosidase expression to promote neural stem cells differentiation into neurons through Wnt\/\u03b2-catenin pathway after ischemic stroke. Front Mol Neurosci. 2020, 13:596039. 10.3389\/fnmol.2020.596039","journal-title":"Front Mol Neurosci"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000535","article-title":"Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol","volume":"5","author":"Colucci F","year":"2023","unstructured":"Colucci F, Avenali M, De Micco R, et al.. Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol. BMJ Neurol Open. 2023, 5:e000535. 10.1136\/bmjno-2023-000535","journal-title":"BMJ Neurol Open"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial","volume":"77","author":"Mullin S","year":"2020","unstructured":"Mullin S, Smith L, Lee K, et al.. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol. 2020, 77:427-34. 10.1001\/jamaneurol.2019.4611","journal-title":"JAMA Neurol"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00883","article-title":"Ambroxol hydrochloride improves motor functions and extends survival in a mouse model of familial amyotrophic lateral sclerosis","volume":"10","author":"Bouscary A","year":"2019","unstructured":"Bouscary A, Quessada C, Mosbach A, Callizot N, Spedding M, Loeffler JP, Henriques A. Ambroxol hydrochloride improves motor functions and extends survival in a mouse model of familial amyotrophic lateral sclerosis. Front Pharmacol. 2019, 10:883. 10.3389\/fphar.2019.00883","journal-title":"Front Pharmacol"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2024.102415","article-title":"A recent update on drugs and alternative approaches for parkinsonism","volume":"104","author":"Kispotta S","year":"2024","unstructured":"Kispotta S, Das D, Prusty SK. A recent update on drugs and alternative approaches for parkinsonism. Neuropeptides. 2024, 104:102415. 10.1016\/j.npep.2024.102415","journal-title":"Neuropeptides"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.852","article-title":"The use of ambroxol for the treatment of Gaucher disease: a systematic review","volume":"5","author":"Abelleyra Lastoria DA","year":"2024","unstructured":"Abelleyra Lastoria DA, Grewal S, Hughes D. The use of ambroxol for the treatment of Gaucher disease: a systematic review. EJHaem. 2024, 5:206-21. 10.1002\/jha2.852","journal-title":"EJHaem"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00025.2020","article-title":"Sodium channelopathies of skeletal muscle and brain","volume":"101","author":"Mantegazza M","year":"2021","unstructured":"Mantegazza M, Cest\u00e8le S, Catterall WA. Sodium channelopathies of skeletal muscle and brain. Physiol Rev. 2021, 101:1633-89. 10.1152\/physrev.00025.2020","journal-title":"Physiol Rev"},{"key":"ref156","article-title":"Pharmacotherapy of the epilepsies","author":"Metcalf CS","year":"2023","unstructured":"Metcalf CS, Smith MD, Wilcox KS. Pharmacotherapy of the epilepsies. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. Brunton LL, Knollmann BC (ed): McGraw-Hill Education, New York, NY; 2023. 385-411."},{"key":"ref157","doi-asserted-by":"publisher","DOI":"10.5455\/medscience.2020.07.136","article-title":"Beneficial effects of ambroxol hydrochloride on pentylenetetrazol-induced convulsion model in rats","volume":"9","author":"Sunnetci E","year":"2020","unstructured":"Sunnetci E, Solmaz V, Hatipoglu HU, Erbas O. Beneficial effects of ambroxol hydrochloride on pentylenetetrazol-induced convulsion model in rats. Med Sci. 2020, 9:978-81. 10.5455\/medscience.2020.07.136","journal-title":"Med Sci"},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000031","article-title":"Ambroxol-induced focal epileptic seizure","volume":"37","author":"Lapenta L","year":"2014","unstructured":"Lapenta L, Morano A, Fattouch J, Casciato S, Fanella M, Giallonardo AT, Di Bonaventura C. Ambroxol-induced focal epileptic seizure. Clin Neuropharmacol. 2014, 37:84-7. 10.1097\/WNF.0000000000000031","journal-title":"Clin Neuropharmacol"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.5414\/cpp44409","article-title":"Safety and usage pattern of an over-the-counter ambroxol cough syrup: a community pharmacy-based cohort study","volume":"44","author":"Schulz M","year":"2006","unstructured":"Schulz M, H\u00e4mmerlein A, Hinkel U, Weis G, Gillissen A. Safety and usage pattern of an over-the-counter ambroxol cough syrup: a community pharmacy-based cohort study. Int J Clin Pharmacol Ther. 2006, 44:409-21. 10.5414\/cpp44409","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref160","doi-asserted-by":"publisher","DOI":"10.4081\/mrm.2020.511","article-title":"An overview of efficacy and safety of ambroxol for the treatment of acute and chronic respiratory diseases with a special regard to children","volume":"15","author":"Kantar A","year":"2020","unstructured":"Kantar A, Klimek L, Cazan D, Sperl A, Sent U, Mesquita M. An overview of efficacy and safety of ambroxol for the treatment of acute and chronic respiratory diseases with a special regard to children. Multidiscip Respir Med. 2020, 15:511. 10.4081\/mrm.2020.511","journal-title":"Multidiscip Respir Med"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.1111\/cga.12557","article-title":"Risk of major birth defects after first-trimester exposure to carbocisteine and ambroxol: a multicenter prospective cohort study using counseling data for drug safety during pregnancy","volume":"64","author":"Usuda M","year":"2024","unstructured":"Usuda M, Jwa SC, Goto M, et al.. Risk of major birth defects after first-trimester exposure to carbocisteine and ambroxol: a multicenter prospective cohort study using counseling data for drug safety during pregnancy. Congenit Anom (Kyoto). 2024, 64:91-8. 10.1111\/cga.12557","journal-title":"Congenit Anom (Kyoto)"},{"key":"ref162","doi-asserted-by":"publisher","DOI":"10.25259\/IJSA_37_2023","article-title":"Ambroxol-induced leukocytoclastic vasculitis: a case report and literature review [in press]","author":"Bhardwaj A","year":"2024","unstructured":"Bhardwaj A, Ghadlinge M. Ambroxol-induced leukocytoclastic vasculitis: a case report and literature review [in press]. Indian J Skin Allergy. 2024, 10.25259\/IJSA_37_2023","journal-title":"Indian J Skin Allergy"},{"key":"ref163","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2007.01474.x","article-title":"Parenteral ambroxol treatment causes xanthine and calcium oxalate stones in rats","volume":"14","author":"Drewa T","year":"2007","unstructured":"Drewa T, Misterek B, Pachnowska H, Wolski Z, Mikulska-Jovanovic M, Drewa J. Parenteral ambroxol treatment causes xanthine and calcium oxalate stones in rats. Int J Urol. 2007, 14:463-5. 10.1111\/j.1442-2042.2007.01474.x","journal-title":"Int J Urol"},{"key":"ref164","doi-asserted-by":"publisher","DOI":"10.1159\/000014005","article-title":"Epidemiology of neonatal acute respiratory disorders. A multicenter study on incidence and fatality rates of neonatal acute respiratory disorders according to gestational age, maternal age, pregnancy complications and type of delivery. Italian Group of Neonatal Pneumology","volume":"74","author":"Rubaltelli FF","year":"1998","unstructured":"Rubaltelli FF, Bonafe L, Tangucci M, Spagnolo A, Dani C. Epidemiology of neonatal acute respiratory disorders. A multicenter study on incidence and fatality rates of neonatal acute respiratory disorders according to gestational age, maternal age, pregnancy complications and type of delivery. Italian Group of Neonatal Pneumology. Biol Neonate. 1998, 74:7-15. 10.1159\/000014005","journal-title":"Biol Neonate"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-15-45","article-title":"Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis","volume":"15","author":"Chenot JF","year":"2014","unstructured":"Chenot JF, Weber P, Friede T. Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis. BMC Fam Pract. 2014, 15:45. 10.1186\/1471-2296-15-45","journal-title":"BMC Fam Pract"},{"key":"ref166","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.2095-1396.2022.06.003","article-title":"Systematic review and meta-analysis of different administration modes of ambroxol hydrochloride in the treatment of respiratory diseases","volume":"12","author":"Yong Z","year":"2022","unstructured":"Yong Z, Tao T. Systematic review and meta-analysis of different administration modes of ambroxol hydrochloride in the treatment of respiratory diseases. Acta Neuropharmacol. 2022, 12:16-24. 10.3969\/j.issn.2095-1396.2022.06.003","journal-title":"Acta Neuropharmacol"},{"key":"ref167","doi-asserted-by":"publisher","DOI":"10.26689\/ijgpn.v2i2.7376","article-title":"Comparative study on the effect of different modes of administration of ambroxol hydrochloride in the treatment of pediatric respiratory diseases","volume":"2","author":"Dong J","year":"2024","unstructured":"Dong J, Zhang L, Jiang X. Comparative study on the effect of different modes of administration of ambroxol hydrochloride in the treatment of pediatric respiratory diseases. Int J Gen Pract Nurs. 2024, 2:77-82. 10.26689\/ijgpn.v2i2.7376","journal-title":"Int J Gen Pract Nurs"},{"key":"ref168","article-title":"[Efficacy of intravenous or atomizing ambroxol for prevention of respiratory distress syndrome in preterm infants]","volume":"8","author":"Hu Q","year":"2006","unstructured":"Hu Q, Lian JM, Li JQ. [Efficacy of intravenous or atomizing ambroxol for prevention of respiratory distress syndrome in preterm infants]. Zhongguo Dang Dai Er Ke Za Zhi. 2006, 8:301-3.","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"ref169","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.5.703","article-title":"Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety","volume":"5","author":"Cuzzolin L","year":"2006","unstructured":"Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf. 2006, 5:703-18. 10.1517\/14740338.5.5.703","journal-title":"Expert Opin Drug Saf"},{"key":"ref170","doi-asserted-by":"publisher","DOI":"10.22541\/au.158878884.49572363","article-title":"Off-label drug use in neonatal intensive care units in China: a descriptive, multicenter study","author":"Lv M","year":"2020","unstructured":"Lv M, Li Y, Sun C, et al.. Off-label drug use in neonatal intensive care units in China: a descriptive, multicenter study. Authorea Preprints. 2020, 1-7. 10.22541\/au.158878884.49572363","journal-title":"Authorea Preprints"},{"key":"ref171","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204427","article-title":"Use of off-label and unlicensed medicines in neonatal intensive care","volume":"13","author":"Costa HT","year":"2018","unstructured":"Costa HT, Costa TX, Martins RR, Oliveira AG. Use of off-label and unlicensed medicines in neonatal intensive care. PLoS One. 2018, 13:e0204427. 10.1371\/journal.pone.0204427","journal-title":"PLoS One"},{"key":"ref172","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2022.12.011","article-title":"Off-label use vs off-label marketing\u00a0of\u00a0drugs: part 1: off-label use-patient harms and prescriber\u00a0responsibilities","volume":"8","author":"Van Norman GA","year":"2023","unstructured":"Van Norman GA. Off-label use vs off-label marketing\u00a0of\u00a0drugs: part 1: off-label use-patient harms and prescriber\u00a0responsibilities. JACC Basic Transl Sci. 2023, 8:224-33. 10.1016\/j.jacbts.2022.12.011","journal-title":"JACC Basic Transl Sci"},{"key":"ref173","doi-asserted-by":"publisher","DOI":"10.1001\/virtualmentor.2012.14.7.oped1-1207","article-title":"Informed consent for off-label use of prescription medications","volume":"14","author":"Mithani Z","year":"2012","unstructured":"Mithani Z. Informed consent for off-label use of prescription medications. Virtual Mentor. 2012, 14:576-81. 10.1001\/virtualmentor.2012.14.7.oped1-1207","journal-title":"Virtual Mentor"},{"key":"ref174","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2006.tb00689.x","article-title":"Off-label use of medicines: consensus recommendations for evaluating appropriateness","volume":"185","author":"Gazarian M","year":"2006","unstructured":"Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006, 185:544-8. 10.5694\/j.1326-5377.2006.tb00689.x","journal-title":"Med J Aust"},{"key":"ref175","doi-asserted-by":"publisher","DOI":"10.1001\/journalofethics.2016.18.6.ecas3-1606","article-title":"Prescribing \"off-label\": what should a physician disclose?","volume":"18","author":"Furey K","year":"2016","unstructured":"Furey K, Wilkins K. Prescribing \"off-label\": what should a physician disclose?. AMA J Ethics. 2016, 18:587-93. 10.1001\/journalofethics.2016.18.6.ecas3-1606","journal-title":"AMA J Ethics"},{"key":"ref176","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.314","article-title":"Going off-label without venturing off-course: evidence and ethical off-label prescribing","volume":"169","author":"Largent EA","year":"2009","unstructured":"Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course: evidence and ethical off-label prescribing. Arch Intern Med. 2009, 169:1745-7. 10.1001\/archinternmed.2009.314","journal-title":"Arch Intern Med"},{"key":"ref177","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0802107","article-title":"Regulating off-label drug use--rethinking the role of the FDA","volume":"358","author":"Stafford RS","year":"2008","unstructured":"Stafford RS. Regulating off-label drug use--rethinking the role of the FDA. N Engl J Med. 2008, 358:1427-9. 10.1056\/NEJMp0802107","journal-title":"N Engl J Med"},{"key":"ref178","doi-asserted-by":"publisher","DOI":"10.1159\/000232592","article-title":"Drug development: from concept to marketing!","volume":"113","author":"Tamimi NA","year":"2009","unstructured":"Tamimi NA, Ellis P. Drug development: from concept to marketing!. Nephron Clin Pract. 2009, 113:c125-31. 10.1159\/000232592","journal-title":"Nephron Clin Pract"},{"key":"ref179","doi-asserted-by":"publisher","DOI":"10.1177\/17470161241247720","article-title":"Research misconduct in China: towards an institutional analysis [in press]","author":"Zhang X","year":"2024","unstructured":"Zhang X, Wang P. Research misconduct in China: towards an institutional analysis [in press]. Res Ethics. 2024, 10.1177\/17470161241247720","journal-title":"Res Ethics"},{"key":"ref180","doi-asserted-by":"publisher","DOI":"10.1057\/s41599-023-02208-6","article-title":"Statistical analysis of research integrity construction in 466 Chinese universities with medical programs","volume":"10","author":"Wang F","year":"2023","unstructured":"Wang F, Zhu C. Statistical analysis of research integrity construction in 466 Chinese universities with medical programs. Humanit Soc Sci Commun. 2023, 10:776. 10.1057\/s41599-023-02208-6","journal-title":"Humanit Soc Sci Commun"},{"key":"ref181","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-00397-x","article-title":"China conducts first nationwide review of retractions and research misconduct","volume":"626","author":"Mallapaty S","year":"2024","unstructured":"Mallapaty S. China conducts first nationwide review of retractions and research misconduct. Nature. 2024, 626:700-1. 10.1038\/d41586-024-00397-x","journal-title":"Nature"},{"key":"ref182","doi-asserted-by":"publisher","DOI":"10.1159\/000243853","article-title":"Antenatal ambroxol effects on surfactant pool size and postnatal lung function in preterm ventilated rabbits","volume":"62","author":"Sun B","year":"1992","unstructured":"Sun B, Rider E, Ikegami M, Jobe A. Antenatal ambroxol effects on surfactant pool size and postnatal lung function in preterm ventilated rabbits. Biol Neonate. 1992, 62:55-62. 10.1159\/000243853","journal-title":"Biol Neonate"},{"key":"ref183","doi-asserted-by":"publisher","DOI":"10.3233\/NPM-200444","article-title":"Commentary - do the negative results of the PENUT trial close the book on erythropoietin for premature infant brain?","volume":"13","author":"Volpe JJ","year":"2020","unstructured":"Volpe JJ. Commentary - do the negative results of the PENUT trial close the book on erythropoietin for premature infant brain?. J Neonatal Perinatal Med. 2020, 13:149-52. 10.3233\/NPM-200444","journal-title":"J Neonatal Perinatal Med"},{"key":"ref184","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2006.02.007","article-title":"Interpretation of the Term Breech Trial findings","volume":"195","author":"Ross S","year":"2006","unstructured":"Ross S, Hannah M. Interpretation of the Term Breech Trial findings. Am J Obstet Gynecol. 2006, 195:1873. 10.1016\/j.ajog.2006.02.007","journal-title":"Am J Obstet Gynecol"},{"key":"ref185","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100476","article-title":"Effect of ambroxol chaperone therapy on glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease","volume":"20","author":"Charkhand B","year":"2019","unstructured":"Charkhand B, Scantlebury MH, Narita A, Zimran A, Al-Hertani W. Effect of ambroxol chaperone therapy on glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease. Mol Genet Metab Rep. 2019, 20:100476. 10.1016\/j.ymgmr.2019.100476","journal-title":"Mol Genet Metab Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/286212-the-potential-of-ambroxol-as-a-panacea-for-neonatal-diseases-a-scoping-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T04:56:10Z","timestamp":1724820970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/286212-the-potential-of-ambroxol-as-a-panacea-for-neonatal-diseases-a-scoping-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":185,"URL":"https:\/\/doi.org\/10.7759\/cureus.67977","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}